PMID- 19895249
OWN - NLM
STAT- MEDLINE
DCOM- 20100329
LR  - 20171116
IS  - 1744-8328 (Electronic)
IS  - 1473-7140 (Linking)
VI  - 9
IP  - 11
DP  - 2009 Nov
TI  - Treatment of malignant gliomas with TGF-beta2 antisense oligonucleotides.
PG  - 1663-74
LID - 10.1586/era.09.138 [doi]
AB  - Antisense oligodeoxynucleotides (AS-ODNs) have been widely used to determine gene 
      function, validate drug targets and as novel therapeutics for human diseases. In 
      this review, we describe the development of AS-ODNs, including their 
      modifications, pharmacokinetics and toxicity in animal models and humans, and 
      their preclinical and clinical development in the therapy of human high-grade 
      gliomas. The most advanced AS-ODN for the therapy of high-grade gliomas is a 
      phosphorothioate-modified AS-ODN, AP 12009 (trabedersen), which targets mRNA 
      encoding TGF-beta2. AP 12009 is administered intratumorally using 
      convection-enhanced delivery. A series of Phase I and II clinical trials have 
      evaluated the toxicity profile and optimal dose of the substance. A randomized, 
      controlled international Phase III study was initiated in March 2009 and will 
      compare trabedersen 10 microM versus conventional alkylating chemotherapy in 
      patients with recurrent or refractory anaplastic astrocytoma after standard 
      radio- and chemotherapy.
FAU - Hau, Peter
AU  - Hau P
AD  - Department of Neurology, University of Regensburg, Medical School, Regensburg, 
      Germany. peter.hau@medbo.de
FAU - Jachimczak, Piotr
AU  - Jachimczak P
FAU - Bogdahn, Ulrich
AU  - Bogdahn U
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Expert Rev Anticancer Ther
JT  - Expert review of anticancer therapy
JID - 101123358
RN  - 0 (Oligodeoxyribonucleotides)
RN  - 0 (Oligonucleotides, Antisense)
RN  - 0 (Thionucleotides)
RN  - 0 (Transforming Growth Factor beta2)
RN  - 98OYR854NY (Trabedersen)
SB  - IM
MH  - Animals
MH  - Brain Neoplasms/drug therapy/metabolism
MH  - Clinical Trials as Topic
MH  - Glioma/*drug therapy/metabolism
MH  - Humans
MH  - Injections, Intralesional
MH  - Oligodeoxyribonucleotides/administration & dosage/genetics/*therapeutic use
MH  - Oligonucleotides, Antisense/administration & dosage/*therapeutic use
MH  - Thionucleotides/administration & dosage/genetics/*therapeutic use
MH  - Transforming Growth Factor beta2/antagonists & inhibitors/*genetics/metabolism
RF  - 87
EDAT- 2009/11/10 06:00
MHDA- 2010/03/30 06:00
CRDT- 2009/11/10 06:00
PHST- 2009/11/10 06:00 [entrez]
PHST- 2009/11/10 06:00 [pubmed]
PHST- 2010/03/30 06:00 [medline]
AID - 10.1586/era.09.138 [doi]
PST - ppublish
SO  - Expert Rev Anticancer Ther. 2009 Nov;9(11):1663-74. doi: 10.1586/era.09.138.